FREEHOLD, N.J. - Avalon GloboCare Corp. (ALBT), a company focused on precision diagnostic consumer products, has entered into a definitive merger agreement with YOOV Group Holding Limited, a provider of business AI automation solutions. The merger is expected to finalize in the third quarter of 2025, pending approval from Avalon stockholders and other customary closing conditions. According to InvestingPro data, ALBT’s stock has shown significant price volatility, with a 121.78% year-to-date return despite recent market fluctuations.
YOOV’s proprietary AIaaS (Artificial Intelligence as a Service) platform has been a significant driver of growth for the company, leading to a 59.1% increase in annual revenue. YOOV reported unaudited revenue of $45.7 million and net income of $3.4 million for the calendar year ended December 31, 2024, in comparison to unaudited revenue of $28.7 million and a net loss of $2.4 million for the prior year. InvestingPro analysis indicates that Avalon’s current financial health score is classified as ’Weak,’ with short-term obligations exceeding liquid assets, suggesting the merger could potentially strengthen its financial position.
The merger is poised to combine Avalon’s expertise in precision diagnostics with YOOV’s advanced AI technology and market presence. The new entity is expected to operate under the name YOOV, Inc. and continue trading on The Nasdaq Capital Market under the ticker symbol YOOV.
Upon completion of the merger, Avalon equityholders are anticipated to own between approximately 2.5% to 2.2% of the combined company’s common stock, with YOOV equityholders owning between approximately 97.5% and 97.8%, depending on Avalon’s common stock market price at the time of the merger’s completion. Based on InvestingPro Fair Value analysis, ALBT appears to be trading above its Fair Value, with 10+ additional ProTips available to subscribers for deeper insights into the company’s valuation and growth prospects.
Phil Wong, Co-Founder and CEO of YOOV, will assume the roles of Chairman, Chief Executive Officer, and President of the merged entity. The board of directors for the combined company will initially consist of seven members, with five designated by YOOV and two by Avalon.
The financial data presented in this announcement is unaudited and based on preliminary internal data, which is subject to change and may differ from the final audited financial statements. The companies have cautioned readers not to place undue reliance on this unaudited financial information.
This merger represents a strategic move to leverage YOOV’s AI technology and Avalon’s diagnostic capabilities, aiming to create value for shareholders and enhance the combined company’s market position. The stock has demonstrated strong momentum with a 38.43% return over the past six months, though investors should note its tendency to move counter to broader market trends, as revealed by its negative beta of -0.1.
The information regarding the merger is based on a press release statement. Avalon and YOOV have not undertaken any obligation to update this information, except as required by law.
In other recent news, Avalon GloboCare Corp. has finalized the sale of its 40% equity interest in Laboratory Services MSO, LLC, for a total consideration of $1.745 million. The sale agreement includes an initial payment of $95,000, followed by monthly installments starting in March 2025. Avalon also announced that it has secured a patent in China for its CAR therapy technology, co-developed with Arbele Limited, which aims to enhance the effectiveness of CAR-T and CAR-NK cell therapies. Additionally, Avalon has entered into an exchange agreement with its Chairman, Wenzhao Lu, to retire its Series A Preferred Stock in exchange for Series D Preferred Stock, marking a notable change in its capital structure.
Further developments include Avalon GloboCare’s agreement with York Sun Investment Holding Limited for the sale of Series C Convertible Preferred Stock valued at $7 million. The first transaction under this agreement has already been completed, with the remaining shares expected to be purchased within 120 days. Meanwhile, Fusion Fuel Green PLC has appointed Luisa Ingargiola as a new director on its Board of Directors, where she will serve as chairperson of the Audit Committee. Ingargiola’s appointment is expected to benefit Fusion Fuel Green’s strategic and financial endeavors. These recent developments highlight significant corporate maneuvers and strategic shifts for both Avalon GloboCare and Fusion Fuel Green.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.